Fennec Pharmaceuticals (NASDAQ:FENC) Stock Rating Upgraded by Stephens

Fennec Pharmaceuticals (NASDAQ:FENC) was upgraded by stock analysts at Stephens to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

A number of other equities research analysts also recently commented on FENC. Wedbush restated an “outperform” rating and issued a $13.00 price objective (down previously from $14.00) on shares of Fennec Pharmaceuticals in a research report on Thursday, November 7th. Craig Hallum reduced their target price on Fennec Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. Finally, HC Wainwright lowered their target price on shares of Fennec Pharmaceuticals from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, August 22nd.

Fennec Pharmaceuticals Stock Up 5.9 %

Shares of Fennec Pharmaceuticals stock opened at $4.28 on Monday. Fennec Pharmaceuticals has a one year low of $3.96 and a one year high of $11.92. The company has a market cap of $117.26 million, a P/E ratio of -42.75 and a beta of 0.27. The company has a debt-to-equity ratio of 9.86, a quick ratio of 7.64 and a current ratio of 7.80. The firm has a fifty day moving average of $4.70 and a two-hundred day moving average of $5.89.

Institutional Investors Weigh In On Fennec Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC purchased a new stake in shares of Fennec Pharmaceuticals in the second quarter valued at about $49,000. The Manufacturers Life Insurance Company acquired a new position in shares of Fennec Pharmaceuticals during the 2nd quarter worth approximately $69,000. Barclays PLC lifted its stake in Fennec Pharmaceuticals by 274.3% in the 3rd quarter. Barclays PLC now owns 31,319 shares of the company’s stock valued at $157,000 after buying an additional 22,951 shares in the last quarter. Rhumbline Advisers grew its holdings in Fennec Pharmaceuticals by 44.7% during the 2nd quarter. Rhumbline Advisers now owns 29,110 shares of the company’s stock valued at $178,000 after buying an additional 8,987 shares during the last quarter. Finally, Advantage Alpha Capital Partners LP purchased a new stake in Fennec Pharmaceuticals during the 3rd quarter worth about $264,000. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.